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Objective: To determine the association of obstructive sleep apnea and nocturnal hypox-
emia with serum lipid profiles in unselected community-dwelling men.
Methods: Cross-sectional data from participants of the Men Androgen Inflammation 
Lifestyle Environment and Stress (MAILES) study (n=753) who underwent full in-home 
polysomnography (Embletta X100) was used. Triglycerides, high- (HDL), low-density 
lipoprotein (LDL), and total cholesterol were assessed on a fasting morning blood sample. 
Multivariable linear regression analyses assessed associations between lipids and continuous 
measures of nocturnal hypoxemia (oxygen desaturation index (3%) (ODI), apnea–hypopnea 
index (AHI), and rapid eye movement sleep apnea–hypopnea index (REM-AHI)), adjusted 
for chronic conditions, risk behavior and sociodemographic factors. Sensitivity analyses 
examined the effect of lipid lowering therapies on reported estimates. Effect modification 
was examined through stratification by waist circumference groups.
Results: In 753 participants with mean (SD) age of 60.8 (10.9) years and waist circumfer-
ence: 99.3 (11.6) cm, the prevalence of OSA (AHI≥10) was 52.6%. Overall, no significant 
associations between OSA metrics and lipid measures were found. Similarly, sensitivity 
analysis excluding lipid lowering therapies showed no significant associations. In analysis 
stratified by waist circumference (<95cm, 95–100cm, >100cm), ODI (3%, unstandardized B: 
0.027, 95% CI: 0.015–0.040), AHI (0.023, 0.012–0.033) and AHIREM (0.012, 0.001–0.022) 
were positively associated with serum triglycerides in participants with a normal waist 
circumference (<95cm).
Conclusion: Obstructive sleep apnea metrics were positively associated with serum trigly-
ceride levels in men with a normal waist circumference. Healthy weight individuals with 
OSA require clinical attention to improve cardiometabolic risk profiles.
Keywords: obstructive sleep apnea, triglycerides, hypoxemia, cohort studies, men, visceral 
obesity
Introduction
Obstructive sleep apnea (OSA) is a syndrome characterized by partial or complete 
obstruction of the upper airways, resulting in intermittent hypoxia, variably accom-
panied by sleep fragmentation and daytime sleepiness.1 In male participants of the 
Swiss HypnoLaus cohort, the prevalence of moderate-to-severe OSA was 49.7%,2 
with 74.7% men aged 40 or over having OSA syndrome according to ICD-3 
criteria.3 However, OSA is often underdiagnosed and unrecognized in clinical 
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settings.4 OSA has been implicated in the development of 
cardiovascular conditions,5 however OSA during rapid eye 
movement (REM) sleep and the resultant nocturnal hypox-
emia are also longitudinally associated with cardiovascular 
disease6 and associated risk factors such as hypertension,7 
insulin resistance,8 metabolic syndrome,9 and carotid 
atherosclerosis.10 Animal models suggest that this 
increased cardiovascular risk is the result of intermittent 
hypoxemia11 leading to activation of the sympathetic ner-
vous system, increased oxidative stress12 and systemic 
inflammation.13,14 Furthermore, chronic intermittent 
hypoxia (CIH) reduced clearance of triglyceride-rich lipo-
proteins and inhibited adipose tissue lipoprotein lipase 
activity.15
Current studies investigating an association between 
OSA and dyslipidemia have shown inconsistent 
results.16–18 This variation may be due to differences in 
study populations, the use of polygraphy rather than poly-
somnography, which may underestimate OSA, and studies 
largely conducted in the clinical setting which may not be 
generalizable to community-based, non-clinical samples. 
In a large clinical sample of adults being investigated for 
OSA, Trzepizur et al19 showed a relationship between 
oxygen desaturation index (ODI) with higher triglycerides 
and lower HDL. In the European Sleep Apnea Database 
Cohort (ESADA), hyperlipidemia was independently asso-
ciated with ODI20 and a positive relationship between 
triglyceride concentration and both ODI and AHI were 
shown.21 A recent study also showed an independent 
association between severe OSA (AHI ≥30/h) with dysli-
pidemia, total cholesterol and LDL cholesterol, with ODI 
shown to be an independent determinant of triglyceride 
levels.22 In a general population sample, HypnoLaus Study 
investigators found that OSA was an independent risk 
factor for incident metabolic syndrome mediated through 
increased nocturnal hypoxemia, however no associations 
with incident metabolic syndrome components including 
high triglyceride or low HDL levels were seen.23
Given the paucity of community-based studies, we 
aimed to determine the association between polysomno-
graphy-measured OSA parameters and nocturnal hypoxe-
mia with serum lipid concentrations in a community 
dwelling cohort (n=753) of adult males. Community- 
based studies are required which can identify atypical/ 
asymptomatic OSA in individuals perceived to be at low 
risk of OSA and its associated cardiometabolic sequelae in 
those who are less likely to be referred for a sleep study. 
We hypothesize that given that central obesity is a strong 
risk factor for both OSA24 and dyslipidemia, it may over-
whelm any contribution of nocturnal hypoxemia to dysli-
pidemia. A few small clinical studies report lipid 
alterations in patients with OSA free of generalized 
obesity23 or with both normal BMI and normal waist 
circumference levels.25,26 Supporting this, a recent study 
using early morning 3-T-1H-magnetic resonance spectro-
scopy of the vastus lateralis muscle in men reported sub-
stantial and most likely transient increases of 
intramyocellular and extramyocellular lipids in non-obese 
men with OSA compared to participants without OSA.27 
Consequently, we conducted analyses stratified by waist 
circumference to observe an obesity-independent associa-
tion between OSA metrics and dyslipidemia.
Materials and Methods
Study Participants
Participants were from the Men Androgens Inflammation 
Lifestyle Environment and Stress Study (MAILES study, 
n=2563 at baseline), a longitudinal study of community- 
dwelling men participating in the North West Adelaide 
Health Study (NWAHS) and Florey Adelaide Male 
Aging Study (FAMAS). Participants were aged at least 
35 years at baseline (2002–2006) and are of predominantly 
European or Australian descent (96%) as previously 
described.28 MAILES participants underwent a computer- 
assisted telephone health interview (CATI) in 2010 
(n=1629), and men who did not report a previous diagno-
sis of OSA on a sleep study (n=1445) were invited to take 
part in a sub-study including polysomnography with 
75.2% agreeing. In 2010–11, 837 men successfully com-
pleted eight-channel in-home unattended polysomnogra-
phy (PSG, Embletta X100, Embla Systems, Broomfield, 
CO, USA) which measured EEG, EOG, EMG, nasal pres-
sure, thoracic and abdominal effort, oximetry, and body 
position. Trained staff visited study participants in their 
homes to set up the PSG equipment. The Pittsburgh Sleep 
Quality Index29 and the Epworth Sleepiness Scale30 were 
administered, and all current medications were recorded. 
Sleep study participants showed minor healthy volunteer 
bias but did not differ in sleep symptoms compared to non- 
sleep study participants.28
Sleep studies were manually scored by a single, trained 
sleep technician according to American Academy of Sleep 
Medicine 2007 alternate criteria (hypopnea defined by a > 
50% decrease in nasal pressure (or in both thoracic and 
abdominal excursions) with an associated 3% oxygen 
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desaturation or an EEG arousal) and recommended for use 
in prospective epidemiological studies by the AASM and 
by an expert panel of the Australasian Sleep Association.31 
Independent variables included the apnea–hypopnea index 
(AHI), rapid eye movement sleep AHI (AHIREM, in parti-
cipants recording at least 30 minutes of REM sleep),7 
AHIREM if AHINREM <10, and oxygen desaturation index 
(ODI, 3%). OSA was defined as AHI≥10/h of sleep, with 
further categorization into mild (AHI 10–19/h sleep), mod-
erate (20–29/h sleep) or severe (≥30/h sleep) as defined by 
the alternate 2007 AASM definition.32 The cut-offs for 
classification were chosen because Ruehland et al32 have 
shown that an AHI of 5/h of sleep used to define sleep- 
disordered breathing scored by the 2007 recommended 
AASM criteria is equivalent to an AHI of 10/h of sleep 
using the alternate AASM definition, and 15/h using the 
older 1999 Chicago criteria. In order to maintain compar-
ability with previous work a cut-off of 10/h was chosen.32
The study was conducted in accordance with the 
Declaration of Helsinki. Study approval was provided by 
the research ethics committees at the Royal Adelaide 
Hospital and North West Adelaide Health Service 
(approval numbers: 2010054, 02305H). Written, informed 
consent was obtained from all participants.
Dependent Variables
Lipid measurements were obtained at clinical assessments 
between 2007 and 2010 on a fasting blood sample taken 
between 8am and 11am after a 12 hour fast. Total choles-
terol, triglycerides, HDL (high-density lipoprotein), LDL 
(low-density lipoprotein), glucose and HbA1c were quan-
tified by an Olympus AU5400 automated chemistry 
analyzer28 in two laboratories of the South Australian 
Department of Health pathology service.
Cardiovascular Risk Factors
Clinic assessment (as previously described)28 included 
anthropometry and blood pressure. Body mass index 
(BMI, Kg/m2) was categorized by World Health 
Organization criteria of underweight/normal <24.9, over-
weight 25.0–29.9 and obese ≥30.0. Systolic and diastolic 
blood pressures were taken using a standard calibrated 
sphygmomanometer, with two measurements taken 5 to 
10 minutes apart and the mean result calculated. 
A definition of systolic blood pressure >140 mmHg and 
diastolic blood pressure >90 mmHg or the use of anti- 
hypertensive medication was used to define hypertension. 
The presence of cardiovascular disease (including 
myocardial infarction, stroke, transient ischemic attack, 
angina) was identified via self-reported questionnaire. 
The presence of diabetes was defined by a doctor's diag-
nosis, HbA1c ≥6.5%, fasting glucose ≥7.0mmol/l or use of 
anti-diabetic medications.
Other Covariates
Socioeconomic factors including age, gender, marital sta-
tus, country of birth, highest education level and gross 
household income were obtained by CATI or self- 
completed questionnaire. Behavioral risk factors including 
smoking status and alcohol consumption were identified 
using a self-reported questionnaire and physical activity 
was assessed with the Active Australia questionnaire.33 
Current use of psychotropic agents (benzodiazepines, opi-
ates, anti-psychotics, anti-depressants) and other sleep dis-
rupting medications (nicotine replacement therapy) was 
identified on the night of the sleep study by staff.28 Lipid 
lowering therapies were classified using the ATC classifi-
cation system34 C10A included plain lipid modifying 
agents (HMG-CoA reductase inhibitors, fibrates, bile acid 
sequestrants, nicotinic acid and derivatives, other lipid 
modifying agents) and C10B combinations of lipid mod-
ifying agents (HMG-CoA reductase inhibitors in combina-
tion with other lipid modifying agents). Depression was 
assessed using the 20-point Centre for Epidemiological 
Studies Depression Scale (CES-D) for NWAHS 
participants35 and the Beck Depression Inventory (BDI- 
1A) for FAMAS participants.36
Principal component analysis was used to identify diet-
ary patterns using data collected by a validated food fre-
quency questionnaire. We identified two dietary patterns – 
western and prudent dietary patterns.37 A prudent dietary 
pattern is based on high dietary intake of vegetables, fruit, 
fish, whole grains, legumes. A western dietary pattern is 
based on high intake of red meat, processed meat, refined 
grains.38 We then used a single diet construct, derived by 
subtracting factor scores of prudent patterns from western 
pattern. A higher diet score represents higher adherence to 
a healthy diet.39
Statistical Analysis
Statistical analysis was conducted using SPSS version 24 
(IBM corporation, Armonk, NY USA). The analytical 
sample is described as mean ± SD or median and inter-
quartile range (IQR) for continuous variables and n(%) for 
categorical variables and tests for differences across waist 
circumference categories included Student’s t-test, 
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independent samples Kruskal–Wallis test and Pearson chi- 
square tests, respectively. Statistical significance was set at 
p<0.05. Those using psychotropic agents (benzodiaze-
pines, opiates, anti-psychotics, anti-depressants) and 
other medications that disrupt sleep (nicotine replacement 
therapy) were excluded (n=84) from the analysis. The 
selection of the analytical sample (n=753) is shown in 
a CONSORT diagram (Figure 1).
Linear regression analysis identified unadjusted, and 
covariate adjusted relationships between sleep para-
meters including AHI, AHIREM (in participants record-
ing at least 30 minutes of REM sleep), AHIREM if 
AHINREM<10, ODI (3%) and lipid measures 
(Model 1). Separate models determined the association 
between sleep parameters and lipid measures, adjusted 
for age, waist circumference, smoking (non/former com-
pared with current), alcohol (non-low risk compared 
with moderate-very high risk), total sleep time, diet, 
depressive symptoms (none compared with at least 
mild depression) and HbA1c (Model 2). We checked 
for collinearity and homoscedastic assumptions. Waist 
circumference was used rather than BMI due to evi-
dence that it is a better predictor of cardiovascular risk 
compared to BMI.40
We further conducted a sensitivity analysis to 
exclude participants on lipid-lowering therapies. Given 
the effects of obesity on OSA and lipid levels, we 
further explored the relationship between triglycerides 
MAILES-3 (2010)
Computer-assisted telephone interview (n=1629)

















Figure 1 Flow diagram of the MAILES study participants. *Sleep-disrupting medications include benzodiazepines, opiates, nicotine replacement therapy, anti-psychotics, anti- 
depressants.
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and AHI, AHIREM, AHIREM if AHINREM<10, and ODI 
(3%), stratified by waist circumference <95cm, 95– 
100cm and over 100 cm. Triglycerides were specifically 
analyzed due to a strong relationship between waist 
circumference and triglycerides, likely mediated through 
insulin resistance41 and due to the minimal effects of 
lipid lowering therapies compared to other lipid mea-
sures. We further conducted binary logistic regression to 
determine associations between clinical categories of 
OSA [no OSA <10/hr, mild (10–19/hr), moderate (20– 
29/hr) and severe (≥30/hr) (27)] and the categorized 
dependent variable – triglyceride (≥ 1.7mmol/L). 
Covariates were the same as for the linear regression 
models.
Results
Participant Characteristics and Sleep 
Measures
The sociodemographic and sleep characteristics of the 
analyzed sample overall and by OSA severity category 
are shown in Table 1. The mean (SD) age was 60.8 
(10.9) years and waist circumference 99.3 (11.6) cm. The 
prevalence of diabetes was 17.1% and hypertension was 
55.4%. Undiagnosed OSA (AHI≥ 10/hr) was determined 
in 52.6% of participants, with severe OSA (AHI ≥30/h) 
present in 12.4%. The characteristics of the sample in 
relation to waist circumference levels are shown in 
Supplementary Table 1.
Relationship Between Sleep Study Metrics 
and Lipids
Covariate unadjusted and adjusted analyses showed no 
significant associations of AHI, AHIREM, REM sleep pre-
dominant AHI (AHIREM if AHINREM<10), or ODI with 
lipid measures (Table 2).
Relationship Between Sleep Study Metrics 
and Lipids in Sample Free from Lipid 
Lowering Therapies
In a sensitivity analysis (n=566), excluding participants 
using lipid lowering therapies (Table 3), there was no 
associations between ODI, AHI, AHIREM, or REM 
sleep predominant AHI (AHIREM if AHINREM<10) 
with lipid measures in co-variate unadjusted or 
adjusted analyses.
Relationship Between Sleep Study Metrics 
and Triglycerides, Stratified by Waist 
Circumference
In analysis stratified by waist circumference to minimize the 
contribution of obesity to hypertriglyceridemia, triglyceride 
levels were positively associated with AHI, ODI and REM- 
AHI in participants with a waist circumference of <95cm 
(Figure 2) in co-variate adjusted analyses (p<0.05). 
Associations were not observed in participants with a waist 
circumference of 95–100cm or >100cm. When we consid-
ered AHIREM in participants with AHINREM <10, the asso-
ciation with triglyceride levels did not persist in men with 
waist circumference <95cm [unstandardized B (SE) =0.004 
(0.008), p=0.60, n=147]. The results remained unchanged in 
men with waist circumference 95–100cm [−0.029 (0.016), 
p=0.076, n=47] and waist circumference >100cm [0.003 
(0.009), p=0.75, n=118].
In analyses based on clinical categories of OSA and 
triglycerides, in males with a waist circumference <95cm, 
severe OSA was significantly associated with an increased 
likelihood of triglyceride levels ≥1.7 mmol/L [OR=4.1 
(95% CI: 1.1–15.5, p=0.039)]. For men with moderate 
OSA, there was an increased likelihood that did not 
reach statistical significance [OR=2.1 (95% CI: 0.7–5.9, 
p=0.17)]. Consistent with the findings of the linear regres-
sion analysis, there were no associations of severe OSA 
with triglyceride ≥1.7 mmol/L in men with waist circum-
ference levels of 95–100cm [OR=0.9 (95% CI: 0.2–4.1, 
p=0.84)] and >100cm [OR=0.7 (95% CI: 0.4–1.5, 
p=0.40)].
Discussion
These data show that in a large, extensively characterized 
cohort of community dwelling men with a mean age of 61 
years, after adjustment for covariates, there was no overall 
significant relationship between any measure of OSA 
metrics and serum lipid profiles. However, after stratifica-
tion by waist circumference, AHI, ODI and AHIREM were 
significantly and positively associated with serum trigly-
ceride concentrations only in men without central 
adiposity.
OSA during REM sleep is characterized by longer 
obstructive events, with greater oxygen desaturations42 
and there is an increasing body of evidence43,44 suggesting 
that compared to obstructive events during non-REM 
sleep, events during REM sleep may be more harmful. 
REM-predominant OSA has been associated with incident 
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Table 1 Demographic, Socioeconomic, Cardiometabolic Conditions, and Sleep Parameters of Study Sample









Age 60.8 ± 10.9 58.9 ± 10.5 62.1 ± 10.8 62.9 ± 10.3 62.9 ± 11.6
BMI 28.6 ± 4.3 27.7 ± 3.8 28.5 ± 4.1 29.4 ± 4.1 31.5 ± 5.3
Waist Circumference 99.3± 11.6 97.0 ± 11.3 99.2 ± 11.8 102.1± 11.3 106.1 ± 12.0
Triglycerides 1.73± 1.64 1.68 ± 0.93 1.77 ± 2.8 1.76 ± 0.97 1.77 ± 0.89
Total Cholesterol 5.22± 1.10 5.25 ± 1.04 5.21 ± 1.22 5.21 ± 1.1 5.06 ± 1.13
HDL 1.32± 0.32 1.32 ± 0.30 1.36 ± 0.33 1.28 ± 0.36 1.26 ± 0.30
LDL 3.15± 0.93 3.21 ± 0.90 3.20 ± 0.99 3.15 ± 0.93 3.04 ± 0.96
HbA1c 5.9± 0.8 5.8 ± 0.66 5.9 ± 0.8 5.9 ± 0.9 6.0 ± 1.0
Household Income, n (%)
Up to $40,000 210 (28.6) 83 (23.8) 58 (30.1) 37 (35.2) 32 (36.4)
$40,001-$80,000 256 (34.9) 124 (35.5) 66 (34.2) 31 (29.5) 35 (39.8)
Over $80,000 234 (31.8) 123 (35.2) 60 (31.1) 33 (31.4) 18 (20.5)
Not stated 35 (4.8) 19 (5.4) 9 (4.7) 4 (3.8) 3 (3.4)
Cardiometabolic Risk Factors and Conditions, n (%)
Current Smoking (n=736) 112(15.2) 61 (17.4) 21 (10.9) 21 (20.0) 9 (10.3)
Alcohol Risk: Intermediate- High (5.5) 15 (4.2) 17 (8.7) 6 (5.7) 3 (3.2)
Cardiovascular Disease* 62(8.2) 22 (6.2) 14 (7.1) 16 (15.0) 10 (10.8)
Physical activity level: Sedentary 561(77.2) 77 (22.4) 41 (21.4) 23 (22.1) 25 (28.5)
Hypertension 403(55.4) 164 (46.9) 111 (58.7) 72 (68.6) 56 (67.5)
Diabetes 127(17.1) 44 (12.4) 42 (21.6) 16 (15.2) 25 (28.4)
BMI>30 252(33.7%) 85 (23.8) 64 (32.7) 48 (44.9) 55 (59.1)
Waist circumference >102cm 291(39.9%) 76 (21.6) 72 (38.3) 56 (53.3) 55 (66.3)
Polysomnography Measures, Median (IQR)
Apnoea-Hypopnea Index (AHI) 10.4 (5.7, 20.6) 5.5 (3.2, 7.9) 14.2 (119, 16.8) 24.2 (21.9–26.8) 41.9 (35.2, 50.7)
AHINREM 9.6 (4.6, 20.1) 4.3 (2.2, 6.7) 13.6 (10.6, 16.5) 24.3 (20.7, 27.5) 43.4 (35.5, 53.1)
AHIREM
‡ 14.0 (6.3, 25.6) 8.1 (4.9, 15.9) 16.5 (9.0, 26.1) 24.5 (11.5–35.0) 36.7 (24.8, 58.3)
Oxygen Desaturation Index 8.0 (3.7, 16.1) 3.7 (2.1, 6.0) 11.5 (8.4, 14.4) 19.5 (16.1, 23.4) 36.3 (28.3, 45.5)
Mean oxygen saturation (%) 94.0 (92.9, 95.1) 94.4 (93.2, 95.4) 93.8 (92.9, 94.9) 93.4 (92.4, 94.6) 93.4 (92.2, 94.4)
Lowest oxygen saturation (%) 86.0 (82.0, 89.0) 88.0 (85.0, 90.0) 86.0 (82.0, 88.0) 82.0 (78.0, 86.0) 80.0 (74.0, 85.0)
% Time spent with Oxygen Saturation 
<90%
0.6 (0.0, 3.7) 0.1 (0.0, 1.0) 0.8 (0.2, 3.1) 2.5 (0.4, 6.1) 5.7 (1.1, 11.4)
NREM Sleep Period (%)
N1 13.9 (10.2, 18.3) 13.6 (9.8, 16.9) 13.1 (9.4, 16.4) 16.2 (11.7, 20.8) 16.6 (12.4, 23.2)
N2 55.6 (49.5, 60.7) 56.7 (50.7, 61.6) 54.6 (49.1, 59.6) 54.6 (47.5, 59.8) 53.6 (46.5, 60.9)
N3 15.4 (9.2, 20.8) 14.8 (8.5, 19.9) 17.0 (12.1, 22.1) 14.3 (9.6, 19.9) 14.7 (6.8, 21.8)
REM sleep period (%) 14.6 (11.4, 18.0) 14.8 (11.6, 17.9) 14.9 (11.8, 17.8) 14.6 (11.2, 18.5) 12.7 (8.7, 17.5)
Pittsburgh Sleep Quality Index, Mean +/ SD
Total score 5.8 ± 3.4 5.8 ± 3.2 5.4 ±3.2 6.1 ± 4.0 6.3 ± 3.6
Notes: The analytical sample (n=753) excludes 84 participants on sleep disrupting medications recorded on the night of the sleep study including benzodiazepines, opiates, 
nicotine replacement therapy, anti-psychotics, anti-depressants. Values represent mean ± standard deviation or number (percentage) for categorical variables. Total numbers 
for each demographic may not correspond to reported number due to small missing values. Units are displayed in brackets. *Myocardial Infarction, Angina, Stroke, Transient 
Ischemic Attack. ‡AHIREM: Rapid eye movement sleep (REM) AHI is calculated for participants with at least 30 minutes of REM sleep. 
Abbreviation: AHINREM, non-rapid eye movement sleep AHI.
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hypertension,7,45 cardiovascular disease,46,47 and glycemic 
control in type 2 diabetes.48 In the current study, we were 
unable to demonstrate a separate contribution of AHIREM 
independent of AHINREM to triglyceride levels. There may 
be a few reasons for this; REM sleep comprised only 15% 
of the sleep time in our study, there may be insufficient 
hypoxic burden present overall if significant OSA is not 
present in NREM sleep. Furthermore, to allow adequate 
observation of REM sleep, we excluded subjects with less 
than 30 min of REM sleep from AHIREM analyses. This 
may have excluded participants most at risk of chronic 
intermittent hypoxia-related lipid abnormalities given that 
severe OSA, or a high frequency of OSA arousals during 
the REM period will result in very short REM sleep.
Our findings regarding AHIREM are consistent with 
a recent clinical cohort study by Xu et al,49 showing 
that associations of AHIREM with increasing serum tri-
glyceride concentration were not independent of 
AHINREM. A small study (15 participants) undertaken in 
Hungary showed that serum lipid profiles were not 
adversely affected by the presence of REM predominant 
OSA.50
Our findings also support other small clinic-based 
patient samples where OSA has been shown to be inde-
pendently associated with serum triglyceride concentra-
tions in individuals with BMI <30 Kg/m2,23 and in 
patients with both normal BMI and normal waist circum-
ference levels),25,26 but not with obesity.51 Of lean patients 
assessed as having OSA (AHI >5/hr and relevant symp-
toms), 39.6% had multiple metabolic abnormalities, 
including serum triglycerides ≥1.7 mmol/L.26 In studies 
of lean participants25,52 with varying severities of OSA 
ranging from mostly mild,44 to mild to severe OSA,40 
compared to the control patients without OSA, those 
with OSA were significantly more likely to demonstrate 
impaired glucose metabolism and insulin resistance.
Animal studies provide evidence for a mechanism link-
ing CIH and lipid abnormalities. In mice, CIH, as occurs in 
Table 2 Multiple Linear Regression Analyses of the Association Between Measures of Nocturnal Hypoxemia and Lipid Profiles in 
Men (n=728§)
Unadjusted Model n=728 Covariate Adjusted Model* n=663
B (SE) p value B (SE) p value
Apnea–Hypopnea Index
Triglycerides 0.004(0.004) 0.35 0.002(0.003) 0.47
HDL -0.001(0.001) 0.21 0.000(0.001) 0.55
LDL -0.002(0.003) 0.38 0.000(0.003) 0.90
Total Cholesterol -0.002(0.003) 0.49 0.001(0.003) 0.82
ODI
Triglycerides 0.004(0.005) 0.37 0.001(0.003) 0.61
HDL -0.001(0.001) 0.13 0.001(0.001) 0.48
LDL -0.001(0.003) 0.78 0.002(0.003) 0.53
Total Cholesterol 0.000(0.003) 0.93 0.002(0.003) 0.49
AHIREM
‡
Triglycerides −0.002(0.004) 0.57 −0.002(0.002) 0.44
HDL -0.001(0.001) 0.22 0.001(0.001) 0.32
LDL -0.001(0.002) 0.62 0.000(0.003) 0.87
Total Cholesterol -0.002(0.003) 0.52 0.000(0.003) 0.99
AHIREM if AHINREM <10/hr
Triglycerides 0.000 (0.005) 0.97 −0.002 (0.005) 0.65
HDL −0.001 (0.002) 0.74 0.000 (0.002) 0.45
LDL −0.004 (0.005) 0.44 −0.003 (0.006) 0.65
Total Cholesterol −0.004 (0.006) 0.47 −0.003 (0.007) 0.65
Notes: *Adjusted for age, smoking, depression, alcohol risk, total sleep time, HbA1c, diet quality, waist circumference. §Analyses excluded participants using sleep 
disrupting medications recorded on the night of the PSG study include benzodiazepines, opiates, nicotine replacement therapy, anti-psychotics, anti-depressants. ‡AHIREM: 
Rapid eye movement sleep (REM) AHI is calculated for participants with at least 30 minutes of REM sleep. In models excluding participants with AHINREM<10, unadjusted 
models n=339; adjusted model n=312. 
Abbreviations: AHINREM, non-rapid eye movement sleep AHI.
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OSA, has been shown to have adverse effects on lipid 
metabolism including increasing hepatic triglyceride pro-
duction, decreasing plasma triglyceride clearance by lipase 
activity inhibition and increased free fatty acid mobilization 
from adipose tissue.15,53 Li et al found that lean, but not 
obese mice, with pre-existing abnormalities of lipid meta-
bolism, exposed to intermittent hypoxia exhibited upregu-
lation of key transcription factors involved in triglyceride 
biosynthesis (SREBP – sterol regulatory element-binding 
protein, SCD-1- SREBP-1 regulated enzyme for lipid 
biosynthesis).54 Insulin inhibits hepatic triglyceride produc-
tion and animal studies have also demonstrated a link 
between intermittent hypoxia and insulin resistance in lean 
mice.55,56 In human studies, Koenig et al27 recently reported 
large overnight CIH-related increases in plasma triglycer-
ides that occurred in non-obese participants with OSA 
compared to participants with obesity and OSA (214.7 
±40.9 cf 95.6 ± 12.6 mg/100mL), and speculate that muscle 
or liver free fatty acid uptake capacity may be exceeded by 
overnight increases in circulating FFAs and may therefore 
be associated with re-esterification of FFAs. In a small 
clinical study of 15 “healthy” men with severe OSA 
(mean WC: 97cm, BMI: 28.4 kg/m2; free of significant 
comorbidities), Drager et al57 reported disturbances in tri-
glyceride-rich lipoprotein metabolism, with correction of 
delayed fractional clearance rates (FCR) of radiolabeled 
triglycerides and cholesteryl ester by 3 months of CPAP 
therapy supporting their earlier work.15 That disrupted sleep 
that occurs in OSA is linked to dyslipidemia is further 
supported by a recent multi-ancestry genome-wide sleep- 
by-single nucleotide polymorphism (SNP) analyses on 
three lipid traits (HDL, LDL, and triglycerides) which 
identified gene-short sleep interactions that explained 
4.25% of the variance in triglyceride levels.58
We therefore suggest based upon our data and the 
results of animal and mechanistic studies that intermittent 
hypoxia due to OSA may induce metabolic derangements 
associated with insulin resistance that cannot be separated 
from the predominant effect of visceral obesity and there-
fore results are observed in lean participants where obesity 
Table 3 Multiple Linear Regression Analyses of the Association Between Nocturnal Hypoxemia Measures and Lipid Profiles in Men 
without Use of Lipid Lowering Therapies or Sleep Disrupting Medications§ (n=566)
Unadjusted Model n=566 Covariate Adjusted Model* n=517
B (SE) p value B (SE) p value
Apnea–Hypopnea Index (AHI)
Triglycerides 0.004(0.003) 0.12 0.003(0.003) 0.36
HDL -0.001(0.001) 0.24 0.000(0.001) 0.78
LDL 0.001(0.003) 0.64 0.001(0.003) 0.65
Total Cholesterol 0.002(0.003) 0.60 0.001(0.003) 0.64
ODI
Triglycerides 0.006(0.003) 0.069 0.002(0.003) 0.47
HDL -0.002(0.001) 0.096 0.000(0.001) 0.85
LDL 0.002(0.003) 0.48 0.002(0.003) 0.48
Total Cholesterol 0.002(0.003) 0.48 0.002(0.004) 0.57
AHIREM
‡
Triglycerides 0.000(0.003) 0.95 −0.004(0.003) 0.19
HDL 0.000(0.001) 0.81 0.002(0.001) 0.081
LDL 0.001(0.002) 0.66 0.000(0.003) 0.86
Total Cholesterol 0.001(0.003) 0.71 0.000(0.003) 0.99
AHIREM if AHINREM <10/hr
Triglycerides −0.001 (0.006) 0.88 −0.002 (0.006) 0.79
HDL 0.001 (0.002) 0.96 0.001 (0.002) 0.70
LDL 0.000 (0.005) 0.94 0.000 (0.006) 0.96
Total Cholesterol 0.000 (0.006) 0.98 −0.001 (0.007) 0.94
Notes: *Adjusted for age, smoking, depression, alcohol risk, total sleep time, HbA1c, diet quality, waist circumference. §Sleep disrupting medications recorded on the night of 
the PSG study included benzodiazepines, opiates, nicotine replacement therapy, anti-psychotics, anti-depressants. ‡AHIREM: Rapid eye movement sleep (REM) AHI is 
calculated for participants with at least 30 minutes of REM sleep. In models excluding participants with AHINREM<10 unadjusted models n=277; adjusted model n=255. 
Abbreviation: AHINREM, non-rapid eye movement sleep AHI.
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Figure 2 Forest plots for the association between triglycerides and AHI, REM-AHI and ODI in males separated into groups by waist circumference (<95cm, 95–100cm, 
>100cm). Coefficients are unstandardized with 95% confidence intervals. Model adjusted for age, smoking, depression, alcohol risk, total sleep time, HbA1c, diet quality. 
Sleep disrupting medications include benzodiazepines, opiates, nicotine replacement therapy, anti-psychotics, anti-depressants.
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does not have a dominant effect. Supporting this, CPAP 
therapy has resulted in an improvement in insulin resis-
tance in non-obese participants to a greater effect than in 
obese participants.59
The current study has several strengths. The partici-
pants were randomly recruited, community-dwelling men 
with extensive phenotypic, clinical, and biochemical 
assessments. They were broadly representative of the 
Australian male population aged 40 and over. The sleep 
subgroup was randomly selected from the whole study 
population, had similar socio-demographic and health- 
related characteristics to the full sample and gold standard 
polysomnography was performed in-home.28 We adjusted 
for co-founders that were clinically relevant or showed 
strong significance in univariate analysis, and we per-
formed sensitivity analysis excluding the use of lipid low-
ering agents. The cross-sectional nature of the study limits 
any inferences about causality, and the findings cannot be 
generalized to younger men or women. Sex-specific rela-
tionships between OSA and serum lipid profiles have pre-
viously been reported.60 Furthermore, our findings from 
a cohort of community-dwelling men with many reporting 
few symptoms may not be generalizable to patients in the 
clinical setting. However, the advantage of population- 
based studies is the ability to identify healthy weight, 
asymptomatic individuals with OSA and cardiometabolic 
risk who would otherwise be unlikely to be referred for 
a sleep study.
Our findings have potential clinical implications. OSA 
has been shown to occur in approximately 5–14% of lean 
men61 who may be perceived as being at low risk of OSA 
and its related cardiometabolic sequelae. The presence of 
obstructive sleep apnea should be considered in the 
workup for elevated serum triglycerides in lean men. 
A recent clinical study reported high prevalence rates of 
metabolic risk in lean patients with OSA (AHI >5/hr, BMI 
<25 kg/m2 and waist <80cm in females; <90 cm in males), 
with dyslipidemia demonstrated in 61%, and two of three 
metabolic syndrome components in 64%.62 Despite this 
high metabolic risk, treatment of hyperlipidemia in clinical 
populations with OSA is not high [eg 12% in the European 
Sleep Apnea Database Cohort (ESADA) cohort].20
OSA treatment with continuous positive airway pres-
sure (CPAP) therapy, however, may not yield desired 
reductions in lipid levels and mainstay therapy with HMG- 
CoA reductase inhibitors and fibrates will be required. As 
reviewed recently,18,63 observational studies and rando-
mized controlled trials (often limited by small sample 
sizes and short follow-up times) have reported inconsistent 
effects of CPAP therapy on lipid parameters. In the 
ESADA Cohort, where higher ODI and AHI were asso-
ciated with lipid parameters,20,21 an observational study of 
at least 3 months of PAP therapy (n=1564) in the cohort 
yielded a mean decrease in total cholesterol of 4.9 mg/dl 
(0.13 mmol/L) after ≥3 months therapy, with no effect on 
triglyceride levels.64 Compliance with CPAP therapy may 
have influenced the inconsistent benefits on lipid para-
meters reported in studies to date as CPAP use less than 
4hrs per night is unlikely to treat REM sleep OSA demon-
strated in our study and others to be relevant for lipid 
measures.49
In conclusion, we have shown that in a population of 
community-dwelling male adults, severe obstructive sleep 
apnea is a risk factor for raised serum triglyceride concentra-
tions in those without central adiposity. This is likely the 
direct consequence of chronic intermittent hypoxia on trigly-
ceride metabolism. Good CPAP compliance over the entire 
night including REM sleep may be beneficial. Further stu-
dies are required to evaluate the relationships between OSA 
and dyslipidemia in lean women and in younger men and to 
determine the effects of CPAP on triglycerides.
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